Poging GOUD - Vrij

Slashing food tariffs: A risky bet

Business Standard

|

July 01, 2025

Why NITI Aayog's push for US market access could hurt India's food security

- AJAY SRIVASTAVA

Slashing food tariffs: A risky bet

A recent NITI Aayog paper recommends sweeping tariff cuts on a range of agricultural imports from the United States — including rice, dairy, poultry, corn, apples, almonds, and genetically-modified soya — as part of the proposed India-US Free Trade Agreement.

The paper, titled "Promoting India-US Agricultural Trade under the new US Trade Regime," was published in May. We look at its key recommendations and what they could mean for India's food security. Let's start with rice — India's staple food across states.

Rice: The paper suggests scrapping import tariffs on US rice, as India already exports large amounts of rice and hence faces little risk from imports. While this argument sounds reasonable at first glance, it overlooks a costly mistake India made in the past.

In the 1960s and early 1970s, India faced food shortages and depended on US food imports under PL-480 — a US law that allowed surplus food to be sold or donated to countries like India.

During global trade talks (Kennedy and Tokyo Rounds of General Agreement on Tariffs and Trade or GATT, 1964-1979), India — then a major food importer— agreed to US proposals to lock its tariffs at zero on key staples like rice, wheat, and skimmed milk powder. This meant India gave up the right to raise tariffs on these items in the future.

Later, the Green Revolution significantly boosted India's farm output, and by the early 1990s, the country had become self-sufficient in rice and wheat. Indian farmers now needed tariff protection from cheap, subsidized imports — but the old GATT commitments left India unable to raise tariffs. The only legal option was to renegotiate under GATT's Article XXVIII, which India did in the 1990s.

MEER VERHALEN VAN Business Standard

Business Standard

Labour Codes impact: HCL tech profit slips 11%

Q3 top line beats Street estimates, bottom line misses expectations

time to read

2 mins

January 13, 2026

Business Standard

New labour Codes, restructuring weigh on TCS earnings

Tata Consultancy Services (TCS), India’s largest information technology (IT) services firm, saw its profit impacted in the October-December quarter by restructuring and changes in labour Codes.

time to read

1 min

January 13, 2026

Business Standard

Business Standard

Black drives the thrill for car buyers

Sees a surge in yearly sales, while white remains practical 'utility king'

time to read

2 mins

January 13, 2026

Business Standard

CHOOSING THE RIGHT B-SCHOOL TO MATCH YOUR CAREER GOALS

Success comes when you pick an institution that fits your professional dreams and your personality, helping you become the leader you want to be

time to read

2 mins

January 13, 2026

Business Standard

Business Standard

China’s PVC rethink to help India pipe makers

Supply likely to tighten after S-PVC rebate withdrawal

time to read

2 mins

January 13, 2026

Business Standard

Responsible growth

India must ensure data centres are sustainable

time to read

2 mins

January 13, 2026

Business Standard

India’s GenZ is full of creativity: PM

Prime Minister Narendra Modi on Monday said India's GenZ is full of creativity and with innovative ideas, energy and purpose, the country’s youth is at the forefront of nation-building.

time to read

1 min

January 13, 2026

Business Standard

Business Standard

Iran wants to negotiate after threats to attack, says Trump

At least 572 killed in protests; Tehran says situation ‘under full control’

time to read

2 mins

January 13, 2026

Business Standard

Insurers knock on Irdai door for clarity on director overlap ban

CLAUSE THREATENS BOARD STRUCTURES AT BANK-BACKED FIRMS SAYS INDUSTRY

time to read

2 mins

January 13, 2026

Business Standard

Delhi HC allows Zydus to sell generic version of cancer drug

Citing public interest, the Delhi High Court has cleared the way for Zydus Life-sciences to proceed with the sale of its version of the cancer drug nivolumab in India.

time to read

1 min

January 13, 2026

Listen

Translate

Share

-
+

Change font size